No abstract

No abstract

Canadian guidelines. A network meta-analysis was conducted to estimate the relative risk (RR) of treatment success with respect to vehicle, which was highest for HP/ TAZ (RR: 4.3) and lowest for TAZ (1.6). For responders, a 41.8% 8-week probability of relapse was applied for all treatments. Those who did not respond to topical treatment were assumed to receive either systemic or biologic treatment. The outcomes were healthcare costs (2018 CAD), quality-adjusted life years (QALYs) and incremental cost effectiveness ratio (ICER) per QALY. Results: HP/TAZ was associated with the lowest costs and highest QALYs over 3 years, which made it a dominant strategy relative to all other comparators.